Various somatic point mutations of IDH1 or IDH2 have been discovered in a variety of malignancies in recent years, such as gliomas and AMLs (acute myeloid leukemias) (Yan et al., 2009; Zhao et al., 2009). This evidence concerns the gene IDH1 and central nervous system cancer.